GRI Bio, Inc.
GRI Bio develops oral RARβ/γ-selective agonist GRI-0621 for idiopathic pulmonary fibrosis and type 2 diverse NKT agonists for systemic lupus erythematosus.
8-KNov 4Latest SEC filing
Nov 4Latest story
November 2026
Sign inSign inGRI Bio develops oral RARβ/γ-selective agonist GRI-0621 for idiopathic pulmonary fibrosis and type 2 diverse NKT agonists for systemic lupus erythematosus.